Business
business
Rani Molla

Amazon is trying to get “low double-digit price cuts” from sellers to offset tariff hits to its margins

To combat margin fallout from the Trump administration’s tariffs on China, Amazon is getting tougher on its suppliers, hoping to extract “low double-digit price cuts” from the sellers, the Financial Times reports.

Amazon sellers, of course, import a big chunk of the platform’s goods from China and have long been squeezed by the e-commerce giant.

The FT noted that Amazon’s playbook was similar during the tariffs from President Trump’s first administration.

Earlier in this Trump administration, Amazon had been moving up shipments from China to get ahead of tariffs. More recently, it’s been outright canceling orders from China.

Goldman Sachs says tariffs could cut 6% to 12%, or $5 billion to $10 billion, from Amazon’s operating profits this year.

The FT noted that Amazon’s playbook was similar during the tariffs from President Trump’s first administration.

Earlier in this Trump administration, Amazon had been moving up shipments from China to get ahead of tariffs. More recently, it’s been outright canceling orders from China.

Goldman Sachs says tariffs could cut 6% to 12%, or $5 billion to $10 billion, from Amazon’s operating profits this year.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.